|Bid||20.00 x 800|
|Ask||51.14 x 1000|
|Day's Range||50.77 - 52.13|
|52 Week Range||24.84 - 52.14|
|Beta (3Y Monthly)||1.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 28, 2019 - Nov 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.75|
Anyone researching Cardiovascular Systems, Inc. (NASDAQ:CSII) might want to consider the historical volatility of the...
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardiovascular Systems, Inc. , a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral
Cardiovascular Systems Inc (CSII) files its latest 10-K with SEC for the fiscal year ended on June 30, 2019. Continue reading...
Cardiovascular Systems, Inc. (CSI®) (CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease (PAD and CAD), presented three-year outcomes from its LIBERTY 360° study in a late-breaking presentation at the 2019 Amputation Prevention Symposium (AMP) in Chicago. The three-year study outcomes were presented at AMP by Dr. Jihad A. Mustapha, MD, FACC, FSCAI, Advanced Cardiac & Vascular Amputation Prevention Centers, Grand Rapids, Michigan.
This study outcome is expected to be a major stride forward in Cardiovascular Systems' (CSII) endeavor to offer treatment to patients of multi-level peripheral artery disease (PAD).
Company introduces Diamondback 360° Exchangeable Series to treat multi-level PAD
We are upbeat about the year-over-year uptick in Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.
Cardiovascular Systems, Inc. , a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management will present and host investor meetings at the 8th Annual Intellisight Conference in Minneapolis, Minn.
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 0.00% and 3.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Cardiovascular Systems, Inc. (CSI®) (CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that it has acquired the WIRION Embolic Protection System and related assets from Gardia Medical Ltd., a wholly owned Israeli subsidiary of Allium Medical Solutions Ltd. (ALMD.TA). Physicians typically use embolic protection devices in vessels located above the knee with long lesions, high plaque burden and poor run off.
Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiovascular Systems touted Paulsen’s support for the medical device industry and involvement with federal healthcare and economic policy in an announcement Thursday.
Today we are going to look at Cardiovascular Systems, Inc. (NASDAQ:CSII) to see whether it might be an attractive...
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
HealthEquity (HQY) is set to acquire WageWorks in an all-cash deal of about $2 billion. The buyout is expected to help HealthEquity to expedite the market-wide transition to HSAs.
Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions.
Stryker (SYK) is gaining steadily from strong international growth and robust product portfolio. However, unfavorable pricing environment remains a woe.